Trending: Pfizer 1Q Earnings Top Estimates; Raises FY24 View
14:19 ET -- Pfizer is one of the most mentioned companies in the U.S. across all news items in the past 12 hours, according to Factiva data. The New York-based biopharmaceutical firm said first-quarter earnings were $3.12 billion, or 55 cents a share, and adjusted earnings came in at 82 cents a share, eclipsing the average analyst estimate of 51 cents. Revenue fell 20%, to $14.88 billion, but easily surpassed the average Wall Street estimate of $13.88 billion. Chairman and Chief Executive Albert Bourla said sales of Covid-19 treatment Paxlovid fell, but demand for blood thinner Eliquis and oncology products such as Ibrance, Xtandi, Padcev and Adcetris bolstered sales. For 2024, Pfizer raised its adjusted earnings per share outlook to $2.15 to $2.35 and said it continues to expect revenue of $58.5 billion to $61.5 billion. This guidance doesn't anticipate any share repurchases in 2024. Dow Jones & Co. owns Factiva. (jennifer.tershak@wsj.com)
(END) Dow Jones Newswires
May 01, 2024 14:34 ET (18:34 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
Which AI Stocks Are Turning Hype Into Revenue?
-
Best- and Worst-Performing Stocks of May 2024
-
3 Stocks to Buy and 3 Stocks to Sell in June
-
Markets Brief: Friday’s Job Report in Focus
-
These Stocks Are (Still) Powering the Bull Market
-
5 Undervalued Energy Stocks to Play the AI Data Center Demand Boom
-
After Earnings, Is Lowe’s Stock a Buy, Sell, or Fairly Valued?
-
5 Stocks With the Largest Fair Value Estimate Cuts After Q1 Earnings
-
What Is Driving Small-Cap Stock Underperformance?
-
After Earnings, Is Zscaler Stock a Buy, a Sell, or Fairly Valued?
-
ASML Fair Value Raised as Outlook Improves
-
The Best Tech Stocks to Buy
-
Undervalued by 40%, This Stock Is a Buy After Earnings
-
After Earnings, Is MongoDB Stock a Buy, a Sell, or Fairly Valued?
-
Where We See Opportunities in June as Stocks Recover Losses
-
10 Top-Performing Dividend Stocks of the Month